BioSpace
Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.
- Update frequency
- every 4 days
- Average duration
- 18 minutes
- Episodes
- 165
- Years Active
- 2023 - 2025
Deals, Dupixent and GLP-1 drug shortages
This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for Dupixent in COPD.
Plus, Merck buys Caraway, Be…
First ever CRISPR gene therapy approval: What happens next?
Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CRISPR/Cas9 gene-edited therapy exagamglogene autotemcel (exa-cel). Will the FDA follow suit? What can pa…
Artificial Intelligence, Part 1: Bias, Access, ROI, Potential Success and Failure
This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and hu…
Zepbound vs Wegovy: A two horse race
Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Elli…
Q3 earnings recap: Winners, losers & surprises
This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on…